基本情報
研究キーワード
4経歴
1-
2009年 - 現在
学歴
2-
- 1987年
-
- 1987年
委員歴
11受賞
12論文
293-
Journal of clinical hypertension (Greenwich, Conn.) 22(3) 465-474 2020年3月Vascular biomarkers, including the cardio-ankle vascular index (CAVI), are increasingly being recognized as important indicators of cardiovascular risk. CAVI has been shown to have good discriminative ability for detecting new-onset hypertension, but results of studies investigating cardiovascular risk prediction are inconsistent. Furthermore, there is a lack of data on the prognostic value of changes in CAVI over time. The Cardiovascular Prognostic Coupling study was designed to determine the impact of baseline CAVI and changes in CAVI on cardiovascular events in a Japanese cohort. The design of the ongoing, multicenter, prospective, observational registry and baseline characteristics of the enrolled population are reported. Eligible consecutive patients were aged ≥30 years, had ≥1 cardiovascular risk factor, and were being treated according to relevant Japanese guidelines. The primary outcome is time to onset of a major cardiovascular event (a composite of cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, stroke of unknown etiology, myocardial infarction, cardiovascular intervention for angina pectoris, and sudden death). Screening and enrollment occurred over a period of 3 years, followed by ≥7 years of follow-up, with CAVI determined annually. A total of 5279 patients were registered, of whom 5109 had baseline data available and will be included in future analyses. Mean CAVI at baseline was 8.8 ± 1.4. The proportion of patients with CAVI of <8, 8-10 or >10 was 25.3%, 57.0%, and 17.7%, respectively. Data from this registry should provide information on the significance of baseline CAVI and change in CAVI as indicators of cardiovascular prognosis in a representative patient population.
-
JACC: Cardiovascular Interventions 13(4) e35-e36 2020年2月24日
-
American journal of hypertension 33(2) 161-164 2020年2月22日
-
Heart View 23(12) 131-137 2019年11月
-
American journal of hypertension 32(11) 1045-1047 2019年10月16日
-
Internal medicine (Tokyo, Japan) 58(18) 2757-2757 2019年9月15日
-
Hypertension 74(3) 564-571 2019年9月1日
-
Journal of Clinical Hypertension 21(9) 1393-1398 2019年9月1日
-
Journal of Clinical Hypertension 21(6) 722-729 2019年6月1日
-
Journal of Clinical Hypertension 21(5) 579-586 2019年5月1日
-
Internal medicine (Tokyo, Japan) 58(9) 1295-1299 2019年5月1日A 68-year-old Japanese man was admitted to our hospital with right eye pain, a sudden worsening of his eyesight, and a fever. He was diagnosed with endogenous bacterial endophthalmitis due to infectious endocarditis (IE) of Group B Streptococcus (GBS) on the day of admission. He recovered systemically, but his right eye became phthisical only with the administration of antibiotics. We conducted a review of the reported cases of IE caused by GBS complicated with endogenous bacterial endophthalmitis. IE should be considered when an undetermined etiology of endogenous endophthalmitis is encountered. The prompt diagnosis and treatment of IE will improve patients' outcomes.
-
Journal of clinical hypertension (Greenwich, Conn.) 21(3) 421-425 2019年3月Constipation is associated with cardiovascular events. Changes to the intestinal microbiota by constipation can induce atherosclerosis, blood pressure rise, and cardiovascular events. Constipation increases with age and often coexists with cardiovascular risk factors. In addition, strain at stool causes blood pressure rise, which can trigger cardiovascular events such as congestive heart failure, arrhythmia, acute coronary disease, and aortic dissection. However, because cardiovascular medical research often focuses on more dramatic interventions, the risk from constipation can be overlooked. Physicians caring for patients with cardiovascular disease should acknowledge constipation and straining with it as important cardiovascular risk, and prematurely intervene to prevent it. The authors review and discuss the relationship between constipation and cardiovascular disease.
-
American Journal of Hypertension 32(3) 282-288 2019年2月12日
-
Pacing and clinical electrophysiology : PACE 42(2) 267-274 2019年2月PURPOSE: Low-dose adenosine triphosphate (LD-ATP) is useful for diagnosing ATP-sensitive atrial tachycardia. However, the clinical implications of the sensitivity of LD-ATP in atrioventricular nodal reentrant tachycardia (AVNRT) still remain unknown. This study aimed to evaluate the mechanism of LD-ATP sensitivity in slow-fast AVNRT. METHODS: We estimated the sensitivity of LD-ATP in slow-fast AVNRT by a 2-4-mg ATP intravenous injection during the tachycardia. We evaluated the atrial-His (A-H) interval, tachycardia termination mode, prevalence of a lower common pathway (LCP), and successful ablation site in slow-fast AVNRT with LD-ATP sensitivity. LCPs were defined as His-atrial interval differences of at least 5 ms between that during ventricular pacing at the tachycardia cycle length and that during the tachycardia. RESULTS: Twenty-eight patients (mean age = 58 ± 11 years old, 18 females) with slow-fast AVNRT, who underwent catheter ablation of the antegrade slow pathway, were enrolled. Seventeen of 28 (61%) patients had LD-ATP sensitivity defined as termination of the tachycardia and/or a prolongation of the A-H interval of over 30 ms after an LD-ATP injection. The patients with LD-ATP sensitivity had a significantly higher prevalence of an LCP than those without (15/17 vs0/11, P < 0.0001). The successful ablation site in the LD-ATP sensitive group was significantly closer to the His bundle area than that in the LD-ATP nonsensitive group (13.3 ± 3.8 vs 20.5 ± 5.4 mm; distance to His bundle area in the left anterior oblique fluoroscopic view, P < 0.0001). CONCLUSIONS: LD-ATP sensitivity in slow-fast AVNRT may suggest the existence of an LCP. The successful ablation site in patients with LD-ATP sensitivity could be closer to the His bundle region.
-
Blood Pressure Monitoring 24(1) 38-41 2019年2月1日
-
Journal of Clinical Hypertension 21(2) 208-216 2019年2月1日
-
Journal of Electrocardiology 52 66-69 2019年1月1日
-
Clinical and experimental hypertension (New York, N.Y. : 1993) 41(8) 774-778 2019年Background: Maximum home systolic blood pressure (maximum SBP) has been reported as a parameter of blood pressure (BP) variability. We tested the hypothesis that maximum SBP is one of the risk factors of hypertensive target organ damage (TOD).Methods: We conducted a cross-sectional study of 4,310 subjects with>1 cardiovascular risk factor. The subjects measured their home BP for 14 consecutive days. Mean and maximum SBPs were used as independent variables. As dependent variables, we used left ventricular mass index (LVMI), brachial-ankle pulse wave velocity (baPWV), maximum carotid intima-media thickness (CIMT), and urine albumin creatinine ratio (UACR).Results: In a multiple regression analysis, the subjects' mean and maximum SBPs were significantly associated with the above TOD markers. Compared to mean SBP, maximum SBP demonstrated a significantly stronger association with CIMT (p<0.001).Conclusion: Based on its clinical significance herein, measurement of maximum home SBP is warranted in addition to measurement of mean home SBP.
-
Blood pressure monitoring 23(6) 283-287 2018年12月OBJECTIVE: This study investigated the changes of ambulatory blood pressure (ABP) profiles on the same participants over a 19-year follow-up. PARTICIPANTS AND METHODS: This is a longitudinal study. We conducted 24-h ABP monitoring at baseline in November 1997 and at follow-up in November 2016 for the same participants who were outpatients in a solitary island clinic. To estimate ambulatory blood pressure variability (ABPV), SD, coefficient of variation, and average real variability of ABP were calculated. ABP levels and ABPV at baseline and follow-up were compared using paired t-test. RESULTS: A total of 35 participants were recruited at follow-up (79.3±6.7 years at follow-up). Mean systolic blood pressure levels in 24-h, daytime, and night-time did not change significantly. However, ABPV of systolic/diastolic blood pressure in 24-h and daytime increased at follow-up compared with baseline (P<0.01 in all variables: SD, coefficient of variation, and average real variability), whereas ABPV in night-time did not change significantly. CONCLUSION: Our observations suggested that 24-h and daytime ABPV increase with aging in community-dwelling elderly people.
-
Expert review of cardiovascular therapy 16(12) 889-895 2018年12月Randomized controlled trials and meta-analyses have established the benefits of blood pressure (BP) lowering. The 2017 American Heart Association/American College of Cardiology (AHA/ACC) guidelines for the management of hypertension established 130/80 mmHg as the threshold for the diagnosis- and treatment-target BP level. Area covered: The global trends are thought to be heading toward intensive BP-lowering management. In this paper, authors summarize the evidence on lowering the BP target in hypertensive patients with a focus on the 2017 AHA/ACC guidelines. Expert commentary: According to the results of clinical research, meta-analyses and the 2017 AHA/ACC guidelines, the target systolic BP may change from less than 140/80 mmHg to 130/80 mmHg in any other international hypertension guidelines. However, this direction of intensive BP control is still controversial.
-
Journal of Clinical Hypertension 20(11) 1633-1641 2018年11月1日
-
Journal of Electrocardiology 51(6) 1099-1102 2018年11月1日
-
Hypertension (Dallas, Tex. : 1979) 72(5) 1133-1140 2018年11月Research suggests that oxygen desaturation and sleep stage during obstructive sleep apnea (OSA) are related to the magnitude of high blood pressure (BP) in a laboratory setting. However, in a clinical setting, these associations have not been well studied. We used a noninvasive oscillometric BP measurement device to investigate the association between oxygen-triggered BP levels at the end of each OSA episode and the characteristics of the preceding OSA episode. In 42 newly diagnosed OSA patients (average age, 63.5±12.5 years; average apnea-hypopnea index, 32.6±18.2 per hour), 258 BP measurements were obtained at the end of OSA episodes. Hypoxia-peak systolic BP (SBP), defined as the maximum oxygen-triggered SBP value, was significantly higher in rapid eye movement sleep (144.9±19.9 mm Hg) than in non-rapid eye movement stage 1 sleep (129.5±15.1 mm Hg; P<0.001) and non-rapid eye movement stage 2 sleep (129.4±14.7 mm Hg; P<0.001). In a multivariate-linear mixed model, the lowest oxygen saturation percentage during each OSA episode was associated with increased hypoxia-peak SBP (-0.501 mm Hg; P<0.001), nocturnal SBP surge (-0.395 mm Hg; P<0.001), defined as the difference between the hypoxia-peak SBP and the mean nocturnal SBP, and maximum value of SBP surge (-0.468 mm Hg; P<0.001), defined as the difference between the hypoxia-peak SBP and the minimum nocturnal SBP independent of sleep stage. These values were not associated with the duration of each OSA episode. The contribution of rapid eye movement sleep and severe oxygen desaturation to OSA-related BP elevation measured with a noninvasive oscillometric method was determined in a clinical setting.
-
Journal of human hypertension 2018年10月 査読有り
-
American journal of hypertension 31(10) 1106-1112 2018年9月 査読有り
-
American journal of hypertension 2018年9月 査読有り
-
Blood pressure monitoring 2018年9月 査読有り
-
Hypertension research : official journal of the Japanese Society of Hypertension 2018年9月 査読有り
-
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 93(5) e27896 2018年9月 査読有り
-
Journal of clinical hypertension (Greenwich, Conn.) 2018年9月 査読有り
-
American journal of hypertension 31(9) 995-1001 2018年8月 査読有り
-
JAMA cardiology 3(7) 583-590 2018年7月 査読有り
-
Circulation journal : official journal of the Japanese Circulation Society 82(8) 2096-2102 2018年7月 査読有り
-
Pulse (Basel, Switzerland) 6(1-2) 1-8 2018年7月 査読有り
-
Pulse (Basel, Switzerland) 6(1-2) 98-102 2018年7月 査読有り
-
The Lancet 391(10137) 2346-2355 2018年6月9日 査読有り
-
Hypertension (Dallas, Tex. : 1979) 71(6) 997-1009 2018年6月 査読有り
-
Journal of Clinical Hypertension 20(6) 1073-1077 2018年6月1日 査読有り
-
Journal of Clinical Hypertension 20(6) 1039-1048 2018年6月1日 査読有り
-
Journal of the American College of Cardiology 71(24) 2858-2859 2018年6月 査読有り
-
Journal of clinical hypertension (Greenwich, Conn.) 20(5) 880-890 2018年5月 査読有り
-
Journal of the American Society of Hypertension 12(5) 340-345.e2 2018年5月1日 査読有り
-
Thrombosis Journal 16(1) 5 2018年3月15日 査読有り
-
Journal of Clinical Hypertension 20(3) 450-455 2018年3月1日 査読有り
MISC
224-
日本循環器学会学術集会抄録集 88回 PJ122-2 2024年3月
-
Hypertension Research 2024年
-
Journal of Clinical Hypertension 23(9) 1681-1683 2021年9月1日
-
Journal of Clinical Hypertension 23(8) 1526-1528 2021年8月1日
所属学協会
11Works(作品等)
2共同研究・競争的資金等の研究課題
28-
日本学術振興会 科学研究費助成事業 2022年4月 - 2027年3月
-
日本学術振興会 科学研究費助成事業 2020年4月 - 2025年3月
-
日本学術振興会 科学研究費助成事業 2020年7月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2019年4月 - 2023年3月
-
日本学術振興会 科学研究費助成事業 2018年4月 - 2023年3月